Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)
19.63
+0.89 (4.75%)
Kiniksa Pharmaceuticals International Plc is a biotechnology company focused on developing innovative therapies for autoimmune and rare diseases
The company is engaged in advancing its pipeline of novel product candidates that target critical unmet medical needs, leveraging its expertise in immunology and inflammation. Kiniksa aims to bring effective treatments to patients through rigorous research and developmental strategies, seeking to improve the quality of life for individuals affected by challenging health conditions.
KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.28% to 35,510.96 while the NASDAQ rose 0.91% to 14,187.05. The S&P 500, also rose, gaining, 0.48% to 4,576.60.
U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Tuesday. Here are some big stocks recording gains in today’s session. Kiniksa Pharmaceuticals, Ltd. (NASDAQKNSA) gained 20.5% to $18.00 following strong quarterly results.
